S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Critical asset just had biggest fall on record (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Tech Genius Reveals #1AI Stock For 2024 (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Tech Genius Reveals #1AI Stock For 2024 (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Critical asset just had biggest fall on record (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Tech Genius Reveals #1AI Stock For 2024 (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Tech Genius Reveals #1AI Stock For 2024 (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Critical asset just had biggest fall on record (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Tech Genius Reveals #1AI Stock For 2024 (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Tech Genius Reveals #1AI Stock For 2024 (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Critical asset just had biggest fall on record (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Tech Genius Reveals #1AI Stock For 2024 (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Tech Genius Reveals #1AI Stock For 2024 (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
NASDAQ:RETA

Reata Pharmaceuticals (RETA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$172.32
$172.46
50-Day Range
$168.70
$172.36
52-Week Range
$21.83
$172.46
Volume
1.99 million shs
Average Volume
1.09 million shs
Market Capitalization
$6.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$157.90

Reata Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.31 Rating Score
Upside/​Downside
8.4% Downside
$157.90 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.02) to ($2.71) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.59 out of 5 stars

Medical Sector

854th out of 932 stocks

Pharmaceutical Preparations Industry

402nd out of 431 stocks


RETA stock logo

About Reata Pharmaceuticals Stock (NASDAQ:RETA)

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.


RETA Stock News Headlines

Clear Buy, Sell, or Hold Recommendation on any Stock, FREE
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Top Growth Stocks for October 2023
Clear Buy, Sell, or Hold Recommendation on any Stock, FREE
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Biogen Completes Acquisition of Reata Pharmaceuticals
Reata Pharmaceuticals (RETA) Gets a Hold from Barclays
Biogen to Acquire Reata Pharmaceuticals
Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?
Expert Ratings for Reata Pharmaceuticals
See More Headlines
Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
2/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RETA
Fax
N/A
Employees
321
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$157.90
High Stock Price Target
$173.00
Low Stock Price Target
$115.00
Potential Upside/Downside
-8.4%
Consensus Rating
Hold
Rating Score (0-4)
2.31
Research Coverage
13 Analysts

Profitability

Net Income
$-311,900,000.00
Pretax Margin
-373.40%

Debt

Sales & Book Value

Annual Sales
$23.48 million
Book Value
($1.79) per share

Miscellaneous

Free Float
27,926,000
Market Cap
$6.58 billion
Optionable
Optionable
Beta
1.42

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report














RETA Stock Analysis - Frequently Asked Questions

Should I buy or sell Reata Pharmaceuticals stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RETA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RETA, but not buy additional shares or sell existing shares.
View RETA analyst ratings
or view top-rated stocks.

What is Reata Pharmaceuticals' stock price target for 2024?

13 equities research analysts have issued 1-year target prices for Reata Pharmaceuticals' shares. Their RETA share price targets range from $115.00 to $173.00. On average, they predict the company's share price to reach $157.90 in the next twelve months. This suggests that the stock has a possible downside of 8.4%.
View analysts price targets for RETA
or view top-rated stocks among Wall Street analysts.

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) issued its quarterly earnings results on Monday, November, 8th. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.32) by $0.35. The company earned $7.40 million during the quarter, compared to the consensus estimate of $2.07 million. The business's revenue was up 428.6% on a year-over-year basis. During the same period in the prior year, the company earned ($1.94) earnings per share.

What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?

10 employees have rated Reata Pharmaceuticals Chief Executive Officer Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among the company's employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an IPO on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray served as the underwriters for the IPO.

This page (NASDAQ:RETA) was last updated on 2/22/2024 by MarketBeat.com Staff